Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184

Naunyn-Schmiedeberg's Archives of Pharmacology
Monika FeliszekEberhard Schlicker


Activation of cannabinoid CB1 receptors may offer new therapeutic strategies, but the efficiency of CB1 receptor agonists may be impaired by tolerance development upon prolonged administration. We compared the influence of repeated administration of Δ(9)-tetrahydrocannabinol (THC) 10 mg/kg on the motility and on basal and CB1 receptor-stimulated (35)S-GTPγS binding of adolescent and aged mice. Moreover, we determined the influence of JZL 184 (which inhibits the 2-arachidonoylglycerol, 2-AG, degrading enzyme monoacylglycerol lipase, MAGL) on (35)S-GTPγS binding and 2-AG levels of young adult mice. Mouse motility was tested in the open field. (35)S-GTPγS binding was studied in hippocampal membranes. THC and CP 55,940 were used as cannabinoid agonists in the behavioural and biochemical studies, respectively. 2-AG levels were quantified by liquid chromatography-multiple reaction monitoring. The THC (10 mg/kg)-induced hypomotility was stronger in untreated than in THC-pretreated adolescent mice but similar in both treatment groups of aged mice. Basal and stimulated (35)S-GTPγS binding was decreased in membranes from THC-pretreated adolescent but not affected in membranes from aged mice. Treatment of young adult mice with JZL 184 (4,...Continue Reading


May 13, 1999·Proceedings of the National Academy of Sciences of the United States of America·A ZimmerT I Bonner
Apr 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Javier González-MaesoJ Javier Meana
May 31, 2002·Pharmacological Reviews·A C HowlettR G Pertwee
Jan 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Lei WangGeorge Kunos
Mar 22, 2003·Clinical Pharmacokinetics·Franjo Grotenhermen
Jul 10, 2003·Lancet Neurology·David BakerAlan J Thompson
Feb 24, 2004·Critical Reviews in Neurobiology·Laura J Sim-Selley
May 29, 2004·Trends in Pharmacological Sciences·Billy R MartinDana E Selley
May 28, 2005·Pharmacology, Biochemistry, and Behavior·Sara GonzálezJavier Fernández-Ruiz
May 28, 2005·Anesthesia and Analgesia·Yan WangPamela Pierce Palmer
May 28, 2005·Anesthesia and Analgesia·Chante Buntin-MushockPamela Pierce Palmer
Oct 14, 2005·Proceedings of the National Academy of Sciences of the United States of America·A Bilkei-GorzoA Zimmer
Apr 7, 2006·Handbook of Experimental Pharmacology·B Szabo, E Schlicker
Oct 31, 2007·The Journal of Pharmacology and Experimental Therapeutics·Diana L McKinneyLaura J Sim-Selley
Nov 26, 2008·Nature Chemical Biology·Jonathan Z LongBenjamin F Cravatt
Jul 2, 2010·British Journal of Pharmacology·Matthew W Buczynski, Loren H Parsons
Jul 30, 2010·The Journal of Pharmacology and Experimental Therapeutics·Nicole L T MooreCynthia M Kuhn
Aug 24, 2010·Nature Neuroscience·Joel E SchlosburgBenjamin F Cravatt
May 3, 2011·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Takako Ohno-ShosakuMasanobu Kano
Jun 22, 2011·Proceedings of the National Academy of Sciences of the United States of America·Onder AlbayramAndras Bilkei-Gorzo
Jul 20, 2011·Journal of Psychopharmacology·S RuehleB Lutz
Jul 19, 2012·Annual Review of Psychology·Raphael Mechoulam, Linda A Parker
Jul 26, 2012·BMC Neuroscience·Leonora E LongCynthia Shannon Weickert
Oct 31, 2012·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Emma PuighermanalAndrés Ozaita
Oct 31, 2012·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Andras Bilkei-Gorzo
Dec 12, 2012·Frontiers in Aging Neuroscience·Onder AlbayramAndreas Zimmer
Jan 3, 2013·Fundamental & Clinical Pharmacology·Panagiotis ZogopoulosStamatios E Theocharis
Jan 30, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Emma PuighermanalAndrés Ozaita
Mar 21, 2013·Pharmacological Reviews·Jacqueline L Blankman, Benjamin F Cravatt
Aug 21, 2013·Neuropharmacology·Daniele Piomelli
Aug 21, 2013·Mechanisms of Ageing and Development·Anastasia PiyanovaAndras Bilkei-Gorzo

❮ Previous
Next ❯


Jan 10, 2018·Frontiers in Molecular Neuroscience·Franciele F ScaranteAlline C Campos
Feb 6, 2020·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J G RamaekersE L Theunissen
Apr 28, 2021·Basic & Clinical Pharmacology & Toxicology·Kennia M SilveiraSâmia R L Joca

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.